Articles On Noxopharm (ASX:NOX)

Title Source Codes Date
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Stockhead NOX 2 weeks ago
Health Check: Sonic Healthcare is cashed up and ready to boom as earnings improve

Sonic reaffirms earnings guidance and says it is on the hunt for “sensible” acquisitions Boards face their inquisitors in peak AGM week Resonance shares soar on Sun Pharma deal   Pathology and radiology giant Sonic Healthcare (ASX:SHL) sa...

Stockhead NOX 1 month ago
Closing Bell: ASX ends Friday in style; NoviqTech explodes 180pc

ASX rises, but MinRes drops over transparency issues Fed boss Powell’s cautious rate cut stance cools market optimism NoviqTech shares surge after securing blockchain funding   The ASX rose by 0.74% on Friday, with 10 out of 11 sectors fi...

Stockhead NOX 1 month ago
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Stockhead NOX 1 month ago
Closing Bell: ASX slips as MinRes rebounds, RBA holds; and are traders exiting ‘Trump trades’?

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

Stockhead NOX 1 month ago
Global Market Update Tech Surge and Oil Eases Pressure

Highlights Tech stocks drive markets higher, with notable movements from Apple and Nvidia. European automobile stocks lifted on improved forecasts, while banking stocks saw slight declines. Commodities, including oil and metals, felt...

Kalkine Media NOX 2 months ago
Health Check: Control Bionics eyes 20pc revenue growth and ‘near term’ profitability

Control Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies the health sector stunners Noxopharm finds a drug manufacturer to kick-start its lupus trial   Health Check is renowned biotech journo Tim Bo...

Stockhead NOX 2 months ago
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Stockhead NOX 2 months ago
Closing Bell: ASX lifts as RBA holds; Element 25 boosts its battery plans with big US grant

ASX down as RBA holds rates steady again Element 25 lands US$166m grant talks Supermarket stocks drop again amid discount claims backlash   The ASX was down 0.3% at one point but rallied to a flattish close after the Reserve Bank kept in...

Stockhead NOX 2 months ago
Closing Bell: ASX steady as coal play Coronado sinks 16pc; NextDC rides on data centre boom

ASX up on Thursday, tech stocks rise boosted by NextDC Wodside Energy drops due to downgrade and oil price fall Iron Ore and coal slide, and Coronado sinks on production and cost issues   After a rough session on Wednesday, the ASX saw a...

Stockhead NOX 3 months ago
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Stockhead NOX 3 months ago
ASX Market Close: Consumer Staples dive on day of flat trading | September 3, 2024

The ASX200 closed fairly flat at 8,103 points. Tomorrow sees the release of crucial Q2 growth numbers and analysts will slice and dice the data in an effort to predict the RBA’s next interest rate move. The Staples sector was aggressi...

themarketonline.com.au NOX 3 months ago
Closing Bell: ASX dips as Woolworths offloads beverage business; Golden Deeps soars 164pc on major find

Today’s Closing Bell is brought to you by WeBull Securities   ASX dipped as Woolworths and mining stocks fell Australia’s current account deficit widened Blackstone acquired AirTrunk’s data centres for $23.5 billion   The ASX dipped 0.08...

Stockhead NOX 3 months ago
Alive and Kicking: Noxopharm has difficult brain cancer in its sights

Noxopharm says two novel drug candidates significantly reduced glioblastoma (brain cancer) cell growth in preclinical models. Percheron Therapeutics announces “very encouraging” new data for its epilepsy program Cyclopharm is off to a soli...

Stockhead NOX 3 months ago
Noxopharm advances Chroma drug platform to target glioblastoma and leukaemia

Noxopharm (ASX: NOX) has made ‘substantial progress’ with its Chroma technology platform, reporting encouraging brain cancer results and early work on leukaemia. The Chroma drug development program focuses on generating first-in-class novel...

SmallCaps NOX 3 months ago
Stocks of the Hour: Golden Deeps, Noxopharm, Echo IQ

  Golden Deeps (ASX:GED) has announced that thick copper and zinc sulphide mineralisation has been intersected in diamond drilling of key targets at the Company’s Havilah Project. The results up to 18.5% Copper & 34.8% Zinc in initial p...

ShareCafe NOX 3 months ago
Top 10 at 11: Copper finds and cancer drugs are in the morning news

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Stockhead NOX 3 months ago
Market Highlights: Oil, iron ore stocks on watch; and should we worry about the ‘September Effect’?

The ASX is likely to open steady as Wall Street was closed Iron ore prices have fallen but remain stable September is historically tough for investors   The ASX is likely to open steady on Tuesday, with Wall Street closed for Labor Day an...

Stockhead NOX 3 months ago
Closing Bell: Windy day for stocks as ANZ, Tabcorp get stung by regulators

ASX ended 10-day winning streak ANZ, Tabcorp dropped after facing regulators Despite a crude price rebound, energy stocks fell   The ASX 200 ended its 10-day winning streak, dipping by 0.04% after a weak session on Wall Street overnight....

Stockhead NOX 4 months ago
ASX Health Stocks: CBL targets more reimbursement revenue for NeuroNode device

Control Bionics to gain US$4,300 reimbursement for its NeuroNode device Noxopharm begins a trial for SOF-SKN, targeting lupus, with results due in 2025 HitIQ signs a two-year deal with Westfield Sports High School   Control Bionics to be...

Stockhead NOX 4 months ago
Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Biotech company Noxopharm Ltd (ASX:NOX) has announced that the first human trial testing SOF-SKN – a novel drug designed to treat autoimmune diseases such as lupus – will begin in Australia next year, leveraging rebates from the federal gov...

themarketonline.com.au NOX 4 months ago
LiveHire claims gold after stellar all-cash takeover bid

This week’s Bulls N’ Bears Runner of the Week is … LiveHire. Its shares rallied 95.83 per cent on an all-cash takeover bid, while other companies to run hard include Artemis Resources, LTR Pharma and Noxopharm.

The West NOX 4 months ago
Closing Bell: ASX climbs as Tech takes charge; CBA, AGL gain on earnings, LiveHire doubles

ASX gained on Wall Street boost and local earnings results CBA, AGL Energy, and Evolution Mining posted strong earnings ASX’s shares dropped after ASIC lawsuit   The ASX extended its gains by on a busy day of earnings reports, up by 0.3%,...

Stockhead NOX 4 months ago
Noxopharm reports CRO-67 breakthrough in pancreatic cancer treatment

Australian biotech company Noxopharm (ASX: NOX) has announced encouraging new data regarding the development of its CRO-67 preclinical drug for pancreatic cancer. The results arise from a study that tested CRO-67 in a complex model of human...

SmallCaps NOX 4 months ago
ASX Health Stocks: Noxopharm soars 40pc on pancreatic tumour-tackling drug results

Noxopharm’s CRO-67 shows significant tumour reduction The drug effectively targets both cancer and protective barrier cells Pro Medicus’ full-year net profit rises 36.5pc   Noxopharm’s drug overcomes tumour barriers Noxopharm (ASX:NOX) ju...

Stockhead NOX 4 months ago
Noxopharm jumps 35% on news its drug CRO-67 reduced human pancreatic tumour cells in mice

Shares in Noxopharm (ASX:NOX) jumped nearly 40% in morning trades on Wednesday according to Cboe live pricing as the company announced its experimental drug CRO-67 reduced human pancreatic tumour cells implanted into mice. The company re...

themarketonline.com.au NOX 4 months ago
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

Stockhead NOX 4 months ago
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Stockhead NOX 4 months ago
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Stockhead NOX 5 months ago
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Stockhead NOX 6 months ago
Australian company Noxopharm joins global alliance for mRNA Medicines

Noxopharm said joining the global alliance means it will connect with other organisations, including CSL and BioNTech, working to progress mRNA and other RNA technologies.

BiotechDispatch NOX 6 months ago
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead NOX 7 months ago
Noxopharm reaches milestone and plans to scale-up production of lupus candidate

Noxopharm (ASX:NOX) is scaling up the production of its preclinical SOF-SKN lupus medication to the standards required for upcoming regulatory submissions.

BiotechDispatch NOX 7 months ago
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Stockhead NOX 7 months ago
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead NOX 7 months ago
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate

Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further inves...

BiotechDispatch NOX 8 months ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead NOX 9 months ago
Closing Bell: Buyers ambush benchmark setting new benchmark

  Local markets started slow before ripping into an all-time intraday high  10 of 11 sectors higher, benchmark closes 0.50pc up Small Caps led by Motio, Cue Energy and Sierra Rutile   Some strong earnings on the last day of February and...

Stockhead NOX 9 months ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead NOX 9 months ago
Closing Bell: Staples go stupid as ASX200 proves it’s no Dow Jones, but it can be average

  Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale   The indignation of Coles has led Consumer...

Stockhead NOX 9 months ago
Closing Bell: The ASX is slightly higher, but not much cooler on Monday

The ASX benchmark has closed slightly higher on Monday Energy Sector gains after oil prices rose over the weekend Small caps led Killi Resources, Nyrada and Viridis Mining   The Aussie sharemarket has ended the opening salvo of the week...

Stockhead NOX 1 year ago
Market Highlights: Microsoft’s new AI chip, why divvy stocks aren’t a sure thing, and 5 small caps to watch

ASX set to fall despite a modest rally on Wall Street Microchip stocks fell as Microsoft unveiled its new custom AI chip Janus Henderson says investing in dividend stocks won’t always be a sure thing   Aussie shares are poised to open low...

Stockhead NOX 1 year ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead NOX 1 year ago
Closing Bell: Even the Aussie dollar appreciates a good lead as dynamic surge makes local IT the it sector for a day

ASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL   The Australian sharemarket has lifted strongly on Day Two of Trading in November, the Best Month for Trading Ever. Local investors got stuck r...

Stockhead NOX 1 year ago
ASX October winners: The 50 best ASX stocks as Israel-Hamas escalation adds further pressure to fragile markets

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

Stockhead NOX 1 year ago
mRNA is the next big thing in medicine. Here’s why Noxopharm could be the ASX front runner in this field

mRNA is set to be the new frontier in vaccines, but has serious side effects including inflammation ASX listed Noxopharm has a program to tackle this problem Stockhead reached out to Stockhead’s CEO, Gisela Mautner   Scientists have been...

Stockhead NOX 1 year ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead NOX 1 year ago
ASX closes 0.3% higher as China’s GDP grows

The Australian sharemarket increased in value on Wednesday, as China's gross domestic product (GDP) for July-September grew by 4.9% compared to the previous year.  At the closing bell, the S&P/ASX 200 was 0.3 per cent higher at 7,077.60...

ShareCafe NOX 1 year ago
Stocks of the Hour: Whitehaven Coal, Paradigm Biopharma, Noxopharm, Liontown Resources

  Don't miss Friday's webinar discussing imaging tech, laser tech and agricultural REITs. Click here to register. Whitehaven Coal (ASX:WHC) has been placed in a trading halt following an announcement by BHP that Whitehaven Coal is the prefe...

ShareCafe NOX 1 year ago
Stocks of the Hour: Whitehaven Coal, Paradigm Biopharma, Noxopharm, Liontown Resources

18 Oct 2023 - A snapshot of the stocks on the move, featuring Whitehaven Coal (ASX:WHC), Paradigm Biopharmaceuticals (ASX:PAR), Noxopharm (ASX:NOX) and Liontown Resources (ASX:LTR)…

FNN NOX 1 year ago